Suppr超能文献

2 型糖尿病患者中糖尿病肾病与糖尿病视网膜病变的时间序列相关性——一项 8 年前瞻性队列研究。

Time-sequential correlations between diabetic kidney disease and diabetic retinopathy in type 2 diabetes - an 8-year prospective cohort study.

机构信息

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

Intelligent Diabetes, Metabolism and Exercise Center, China Medical University Hospital, Taichung, Taiwan.

出版信息

Acta Ophthalmol. 2021 Feb;99(1):e1-e6. doi: 10.1111/aos.14487. Epub 2020 Jun 22.

Abstract

PURPOSE

To investigate the time-sequential correlations between progression/remission of diabetic kidney disease (DKD) and development of diabetic retinopathy (DR) or diabetic macular oedema (DME) in type 2 diabetes (T2D).

METHODS

This was an 8-year prospective cohort study in which 576 patients with T2D and microalbuminuria from one medical centre in Taiwan were recruited. Progression of microalbuminuria was defined as shift of urinary albumin/creatinine ratio (ACR) into 300 mg/g or more; remission of microalbuminuria was defined as having a urinary ACR less than 30 mg/g in at least two of three tests over a period of 6 months. Cox regression analysis was used to evaluate the hazard ratios (HRs) for progression or remission of microalbuminuria on development of any DR, proliferative DR (PDR) and DME.

RESULTS

After adjusting for baseline characteristics , remission of microalbuminuria was a significant protecting factor for development of PDR (HR = 0.290, 95% CI: 0.102-0.826, p = 0.020) and DME (HR = 0.404, 95% CI: 0.188-0.864, p = 0.020). After further adjustment for the mean follow-up HbA1c and systolic blood pressure, remission of microalbuminuria was still a significant protecting factor for development of PDR (HR = 0.348, 95% CI: 0.122-0.992, p = 0.048).

CONCLUSIONS

Remission of microalbuminuria was an independent protecting factor for development of PDR and DME. Aggressive treatment for DKD might help prevent the progression of DR.

摘要

目的

探讨 2 型糖尿病(T2D)患者糖尿病肾病(DKD)进展/缓解与糖尿病视网膜病变(DR)或糖尿病黄斑水肿(DME)发展之间的时间序列相关性。

方法

这是一项在台湾一家医疗中心进行的为期 8 年的前瞻性队列研究,共招募了 576 名 T2D 合并微量白蛋白尿的患者。微量白蛋白尿的进展定义为尿白蛋白/肌酐比值(ACR)转为 300mg/g 或更高;微量白蛋白尿的缓解定义为在至少两次的连续 6 个月内,有三次测试中尿 ACR 均小于 30mg/g。Cox 回归分析用于评估微量白蛋白尿进展或缓解对任何 DR、增殖性 DR(PDR)和 DME 发展的风险比(HR)。

结果

在调整了基线特征后,微量白蛋白尿的缓解是 PDR(HR=0.290,95%CI:0.102-0.826,p=0.020)和 DME(HR=0.404,95%CI:0.188-0.864,p=0.020)发展的显著保护因素。在进一步调整平均随访期间的 HbA1c 和收缩压后,微量白蛋白尿的缓解仍然是 PDR 发展的显著保护因素(HR=0.348,95%CI:0.122-0.992,p=0.048)。

结论

微量白蛋白尿的缓解是 PDR 和 DME 发展的独立保护因素。积极治疗 DKD 可能有助于预防 DR 的进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验